At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
LBH589drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
In Brief
A Phase 2 clinical trial evaluating LBH589 for Waldenstrom's Macroglobulinemia. Completed, enrolled 39 participants across 2 sites.
Detailed Summary
The purpose of this research study is to assess the overall response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. LBH589 is a newly discovered compound that has killed Waldenstrom cells in laboratory studies, however, it is not known if LBH589 will show the same activity in people with Waldenstrom's Macroglobulinemia. This drug has been used in research for the treatment of other types of cancer, such as multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom's Macroglobulinemia
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Novartis
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionSep 2011
Study CompletionNov 2012
TodayJul 2026
First PostedJul 10, 2009
Enrollment StartJul 1, 2009
Primary CompletionSep 1, 2011
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.0 years ago
Interventions
LBH589drug